Beer TM - Search Results

1

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Graff JN, et al. Among authors: beer tm. Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547. Oncotarget. 2016. PMID: 27429197 Free PMC article. Clinical Trial.

2

Complications of chemotherapy for prostate cancer.

Beer TM, Bubalo JS. Beer TM, et al. Semin Urol Oncol. 2001 Aug;19(3):222-30. Semin Urol Oncol. 2001. PMID: 11561990 Review.

3

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

Beer TM, Pierce WC, Lowe BA, Henner WD. Beer TM, et al. Ann Oncol. 2001 Sep;12(9):1273-9. doi: 10.1023/a:1012258723075. Ann Oncol. 2001. PMID: 11697840 Free article. Clinical Trial.

4

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.

Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Beer TM, et al. J Clin Oncol. 2003 Jan 1;21(1):123-8. doi: 10.1200/jco.2003.05.117. J Clin Oncol. 2003. PMID: 12506180 Clinical Trial.

5

Intermittent chemotherapy in metastatic androgen-independent prostate cancer.

Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Beer TM, et al. Br J Cancer. 2003 Sep 15;89(6):968-70. doi: 10.1038/sj.bjc.6601232. Br J Cancer. 2003. PMID: 12966410 Free PMC article. Clinical Trial.

6

Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.

Wagner M, Garzotto M, Lemmon D, Eilers KM, Beer TM. Wagner M, et al. Among authors: beer tm. Urology. 2005 Apr;65(4):799. doi: 10.1016/j.urology.2004.10.059. Urology. 2005. PMID: 15833548

7

High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.

Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. Tiffany NM, et al. Among authors: beer tm. J Urol. 2005 Sep;174(3):888-92. doi: 10.1097/01.ju.0000169261.42298.e6. J Urol. 2005. PMID: 16093981 Clinical Trial.

8

Calcitriol in the treatment of prostate cancer.

Beer TM, Myrthue A. Beer TM, et al. Anticancer Res. 2006 Jul-Aug;26(4A):2647-51. Anticancer Res. 2006. PMID: 16886675 Free article. Review.

9

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators. Beer TM, et al. J Clin Oncol. 2007 Feb 20;25(6):669-74. doi: 10.1200/JCO.2006.06.8197. J Clin Oncol. 2007. PMID: 17308271 Clinical Trial.

10

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.

Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Graff JN, et al. Among authors: beer tm. J Urol. 2007 Apr;177(4):1307-12. doi: 10.1016/j.juro.2006.11.054. J Urol. 2007. PMID: 17382720 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters